Grant ID RP170245
Awarded On November 16, 2016
Title Discovery of antibody-drug conjugates targeting a receptor broadly expressed in solid tumors
Program Academic Research
Award Mechanism Bridging the Gap: Early Translational Research Awards
Institution/Organization The University of Texas Health Science Center at Houston
Principal Investigator/Program Director Qingyun Liu
Cancer Sites Breast, Colorectal, Ovary
Contracted Amount $1,000,000
Lay Summary

Antibody-drug conjugates (ADCs) are monoclonal antibodies (mAbs) that are covalently linked to cell-killing drugs and have emerged as a major modality in anti-cancer treatment. This approach combines high specificity of mAbs against their antigen targets with highly potent cytotoxic drugs, resulting in “armed” mAbs that deliver the payload (drug) to tumor cells with enriched levels of the antibody target. As antibody engineering and linker-payload optimization are becoming more and more mature, the discovery and development of new ADCs is increasingly dependent on the identification and validation new targets that are suitable to this approach. LGR4 is a seven transmembrane domain recept...

Read More